Introduction {#section5-1179544119890853}
============

Gout is strongly associated with comorbidities, including obesity, metabolic syndrome, type II diabetes, hyperlipidemia, hypertension, chronic kidney disease (CKD), and coronary artery disease.^[@bibr1-1179544119890853][@bibr2-1179544119890853]-[@bibr3-1179544119890853]^ Comorbidities frequently restrict conventional treatment options (ie, nonsteroidal anti-inflammatory drugs \[NSAIDs\], colchicine, corticosteroids) for gout flares.^[@bibr3-1179544119890853]^ Acute gout flares are mediated by NLRP3 inflammasome activation with consequent interleukin-1β (IL-1β) release.^[@bibr4-1179544119890853]^ Interleukin-1 (IL-1) antagonism, using the IL-1β-specific antibody canakinumab, is approved in Europe for gout flare. Off-label prescription of the soluble IL-1 receptor antagonist anakinra has been reported effective in case series,^[@bibr5-1179544119890853][@bibr6-1179544119890853][@bibr7-1179544119890853][@bibr8-1179544119890853][@bibr9-1179544119890853]-[@bibr10-1179544119890853]^ including in hospitalized inpatients.^[@bibr11-1179544119890853][@bibr12-1179544119890853][@bibr13-1179544119890853]-[@bibr14-1179544119890853]^ Anakinra was noninferior to conventional approved therapies for acute gouty arthritis in a recent controlled trial.^[@bibr15-1179544119890853]^ To add insight, for clinical medicine, on baseline characteristics, and long-term mortality risk, in patients who ultimately received ⩾1 rheumatologist-prescribed anakinra courses for acute gout, we conducted a randomized, case-control study.

Methods {#section6-1179544119890853}
=======

We focused on a Veterans Affairs (VA) hospital group rheumatology practice, where anakinra pre-authorization was needed, with prescriptions limited to stringent managed care principles, for contraindication or failure of conventional acute gout therapies. VA San Diego Healthcare System Human Subjects Committee ethics board approved (\#130245) the study of electronic records of 1451 patients fulfilling 2015 ACR/EULAR gout criteria,^[@bibr16-1179544119890853]^ and seen by rheumatology between January 1, 2003 and January 27, 2015. All reviewed material was fully de-identified, retrospective information. A total of 13 patients received anakinra for gout flare, with demographics shown in [Figure 1](#fig1-1179544119890853){ref-type="fig"}.

![Flow diagram for patient selection and study design. VA indicates Veterans Affairs.](10.1177_1179544119890853-fig1){#fig1-1179544119890853}

In retrospective case-control analyses, 4 age- and sex-matched controls were chosen (by randomization) for each patient who received anakinra ([Figure 1](#fig1-1179544119890853){ref-type="fig"}). Control selection used search criteria in health records: gout diagnosis by International Classification of Diseases---Ninth Revision (ICD-9) coding, ⩾1 visit to VA rheumatology clinic or inpatient rheumatology consultation, and no recorded anakinra use. The first recorded rheumatology clinical encounter during the study period was analyzed. Gout flares were defined by validated criteria.^[@bibr17-1179544119890853]^ Factor analysis of mixed data (FAMD), to explore similarities between all variables (quantitative and qualitative) for all individuals, was performed using FactoMineR (version 1.39) within the R environment (version 3.4.3).^[@bibr18-1179544119890853],[@bibr19-1179544119890853]^ Relative risk (RR) was calculated as described by Altman.^[@bibr20-1179544119890853]^

Results {#section7-1179544119890853}
=======

At initial rheumatology visit, patients ultimately receiving anakinra more frequently had palpable tophi and higher serum urate ([Table 1](#table1-1179544119890853){ref-type="table"}). There were no significant differences in the mean number of selected comorbidities (mean of 3.9 in anakinra, 3.1 in controls, *P* = .11, confidence interval \[CI\] = --0.18 to 1.67; [Table 1](#table1-1179544119890853){ref-type="table"}), but ultimate all-cause mortality was greater in those who had received anakinra for acute flare (\[6/13\] vs controls \[7/52\], RR = 3.43, 95% CI = 1.39-8.48, *P* = .0076). East Asian patients were more likely to be treated with anakinra ([Table 1](#table1-1179544119890853){ref-type="table"}).

###### 

Overview of demographics of patient populations and clinical profiles.

![](10.1177_1179544119890853-table1)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  All patients (n = 65)              Anakinra group (n = 13)   Control group (age and sex matched) (n = 52)   *P* value^[a](#table-fn3-1179544119890853){ref-type="table-fn"}^   *P* value^[b](#table-fn4-1179544119890853){ref-type="table-fn"}^
  ---------------------------------- ------------------------- ---------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------
  Clinical profile                                                                                                                                                               

   Palpable tophus detected, n (%)   **10/13 (77)**            **16/52 (31)**                                 **.003**                                                           **.03**

   Serum uric acid (mg/dL)           **10.66**                 **7.65**                                       **\<.001**                                                         **.02**

   Mean number of comorbidities      3.92                      3.18                                           .112\                                                              .31
                                                                                                              CI = --0.18 to 1.67                                                

   Diabetes, n (%)                   7 (54)                    19 (37)                                        .35                                                                .58

   Hypertension, n (%)               12 (93)                   39 (75)                                        .27                                                                .49

   CKD---stage 3 or greater, n (%)   **8 (62)**                **13 (25)**                                    **.02**                                                            .09

   CHF, n (%)                        4 (31)                    10 (20)                                        .45                                                                .71

   Obesity, n (%)                    8 (62)                    33 (64)                                        1.00                                                               1.00

  Ethnicity, n (%)                                                                                                                                                               

   Black                             1 (7)                     8 (15)                                         .67                                                                .87

   East Asian                        **7 (54)**                **16 (31)**                                    **.04**                                                            .15

   White                             5 (39)                    29 (56)                                        1.00                                                               1.00

   Hispanic                          0 (0)                     4 (7)                                          .58                                                                .84

  Medications at baseline, n (%)                                                                                                                                                 

   Urate-lowering therapy            7 (54)                    17 (33)                                        .21                                                                .45

   NSAIDs                            6 (47)                    26 (50)                                        1.00                                                               1.00

   Steroids                          3 (23)                    10 (20)                                        .72                                                                .87

   Colchicine                        8 (62)                    17 (33)                                        .11                                                                .31

   Metformin                         2 (16)                    6 (12)                                         .66                                                                .87

   Insulin                           3 (23)                    5 (10)                                         .20                                                                .45

   Loop diuretics                    4 (31)                    8 (16)                                         .24                                                                .47

   Statins                           **9 (70)**                **15 (29)**                                    **.01**                                                            .08

   Thiazides                         1 (8)                     3 (6)                                          1.00                                                               1.00
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CHF, congestive heart failure; CI, confidence interval; CKD, chronic kidney disease; NSAIDs, nonsteroidal anti-inflammatory drugs.

Bold font for individual *P* values indicates statistical significance.

Uncorrected *P* values calculated using unpaired *t* tests.

*P* values corrected by the Benjamini-Hochberg procedure for multiple comparisons.

Most patients had several anakinra courses for gout flares and responded and tolerated anakinra well (not shown). Although the cause of death for several patients in the anakinra treatment group remains unknown, congestive heart failure (CHF) decompensation as precipitant was confirmed in 2 and septic shock (approximately 12 months from the last anakinra dose) in 1 who had received the most courses of anakinra ([Table 2](#table2-1179544119890853){ref-type="table"}). By comparison, of 52 controls, 7 died during the study period ([Table 2](#table2-1179544119890853){ref-type="table"}). Two patients were found dead at home and 3 died from complications of metastatic neoplasms. One with end-stage renal disease had a cardiac arrest during dialysis and 1 with neurogenic bladder died from renal failure, after declining dialysis.

###### 

Details related to anakinra use and ultimate mortality in the anakinra treatment group.

![](10.1177_1179544119890853-table2)

  Patient   Number of courses of anakinra     Response to anakinra (determined by treating physician)   Side effects                     Re-flare in 21 days or less                                                                              Cause of death, if applicable
  --------- --------------------------------- --------------------------------------------------------- -------------------------------- -------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------
  1         3 courses (100 mg/day × 5 days)   Excellent (complete and rapid response)                   None                             1 repeat flare in 3 days after the first course. 1 repeat flare at 14 days after the second course       N/A
  2         1 course (100 mg/d × 3 days)      Substantial                                               None                             Repeat flare at 7 days post cessation                                                                    N/A
  3         8 courses (100 mg/d × 3-5 days)   Excellent                                                 Nonspecific malaise, dizziness   Minor flares at different sites within 14 days post cessation for the last 3 flares requiring anakinra   *Clostridium difficile* infection, health-care-associated pneumonia, renal failure
  4         1 course (100 mg/d × 3 days)      Excellent                                                 None                             Re-flare in 14 days post cessation                                                                       N/A
  5         1 course (100 mg/d × 3 days)      Lost to follow-up                                         Lost to follow-up                Lost to follow-up                                                                                        N/A
  6         1 course (100 mg/d × 21 days)     Excellent                                                 Injection site reaction          Re-flare in 14 days post cessation                                                                       N/A
  7         1 course (100 mg/d × 5 days)      Substantial                                               None                             Flare still ongoing (but improved) at 21 days post anakinra                                              N/A
  8         1 course (100 mg/d × 3 days)      Excellent                                                 None                             Lost to follow-up                                                                                        N/A
  9         1 course (100 mg/d × 3 days)      Substantial                                               None                             Re-flare at different sites in \<21 days post anakinra                                                   Unknown
  10        1 course (100 mg/d × 5 days)      Poor                                                      None                             No repeat flare within 21 days                                                                           CHF decompensation
  11        2 courses (100 mg/d × 3 days)     Substantial                                               None                             No repeat flare within 21 days                                                                           Unknown
  12        1 course (100 mg/d × 14 days)     Substantial                                               Injection site reaction          No repeat flare within 21 days                                                                           CHF decompensation
  13        1 course (100 mg/d × 5 days)      Excellent                                                 None                             No repeat flare within 21 days                                                                           Unknown

Abbreviations: CHF, congestive heart failure; N/A, not applicable.

Factor analysis of mixed data was applied to the qualitative variables shown in [Figure 2](#fig2-1179544119890853){ref-type="fig"}, as well as estimated glomerular filtration rate (eGFR), total number of comorbidities per individual, and uric acid level (quantitative variables), for all individuals. Here, 35.51% of total variance of the data is represented within the first 2 dimensions. Eventual anakinra use was most strongly associated with baseline palpable tophus, and statin or urate-lowering therapy (ULT), which was exclusively allopurinol. There was distinct clustering, with either insulin or loop diuretic use, of death during the observation period ([Figure 2](#fig2-1179544119890853){ref-type="fig"}). Increased mortality with antecedent anakinra prescription for acute gout essentially was linked strongly to comorbidities ([Figure 2](#fig2-1179544119890853){ref-type="fig"}).

![Contribution of categorical variables to the first and second dimensions of a factor analysis of mixed data. Categories of the categorical data groups are labeled on the plot regarding their contribution to the first dimension (*x*-axis) and the second distinct grouping of death with either insulin or loop diuretic use. Dim 1 indicates dimension 1 representing 24% of the variance of the analyzed variables; NSAIDs, nonsteroidal anti-inflammatory drugs; ULT, urate-lowering therapy; Dim2, dimension 2 representing 11.8% of the variance of the analyzed variables.](10.1177_1179544119890853-fig2){#fig2-1179544119890853}

Discussion {#section8-1179544119890853}
==========

Our study highlights that one of the strongest predictors of anakinra use for gout flare treatment is that other options are constrained by comorbidities. Patients requiring anakinra also were more likely to have greater serum urate elevation and tophaceous disease at baseline visit, East Asian descent, and, at the end of the observation period, higher mortality. Bevis et al^[@bibr21-1179544119890853]^ identified 4 clusters in a cross section of gout comorbidity clustering: C1 (elderly with frequent gout attacks; 97% with CKD), C2 (isolated gout and frequent alcohol intake), C3 (hypertension, diabetes, hyperlipidemia, coronary heart disease, and/or CKD were most prevalent and this group had the highest frequency prescription of ULT), and C4 (obese and with hypertension). Here, anakinra recipients appeared to fall under cluster 3, with associated ULT and statin use. Gout is associated with premature mortality.^[@bibr22-1179544119890853]^ Here, the death signal on factor analysis was tightly linked to insulin and loop diuretic use, thereby implicating comorbid diseases. Patients with more comorbidities, especially atherosclerosis, could have elevated systemic inflammation, potentially predisposing to more severe attacks of gout. Cardiovascular disease is more prevalent in gout than controls.^[@bibr23-1179544119890853]^ Here, 22% of all patients had CHF and 81% had hypertension. East Asians (particularly Pacific Islanders) were disproportionately represented in anakinra recipients, but confounders and bias as well as low subject numbers may have contributed to this observation. Larger-scale studies would be indicated to identify and validate any potential genetic predisposition, such as by *ABCG2* variant Q141K,^[@bibr23-1179544119890853]^ to higher inflammatory state and comorbidities in gout.^[@bibr24-1179544119890853]^

Limitations of this study include that case-control studies have high susceptibility to bias, but performing the study in the same VA group was an effort to reduce such issues. A relatively complex VA patient population with prevalent comorbidities was examined, which, as in other VA-based studies, imposes contraindications to the use of NSAIDs, colchicine, or corticosteroids.^[@bibr3-1179544119890853]^ Additional limitations included exclusively retrospective analyses, small sample size, men only receiving anakinra, and quite high prevalence of minority ethnic and racial groups.

In summary, the patient profile for anakinra prescription for acute gout was associated with specific characteristics at baseline rheumatology visit. These included uncontrolled hyperuricemia and a high body urate burden (reflected by palpable tophi), as well as East Asian descent, and a significantly increased number of comorbidities that could heighten systemic inflammation and predispose to continuing symptomatic gout. The increased all-cause mortality signal in this study, associated with prior use of anakinra for acute gout flare, was linked to higher comorbidity burden, especially cardiovascular disease.
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